NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Chengdu Maxvax Biotechnology

Chengdu Maxvax Biotechnology

Private
ChengduHealthcare & Life Scienceshttps://maxvax.cn/

Last Round

Series D

Extension

Dec 25, 2025

Total Funding Raised

$359.84M

Company Overview

Chengdu Maxvax Biotechnology is a biopharmaceutical company that specializes in the research, development, manufacturing, and commercialization of innovative vaccines and novel adjuvants.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Clinical Trials, Precision Medicine

Business Model

B2B

Customer Profile

Services & Consulting, Data as a Service

AI Layer

Non-AI

Keywords

vaccine developmentadjuvant technologyrecombinant protein vaccinemRNA vaccinebiotech CDMOcontract development and manufacturing organizationCDMObiopharmaceutical manufacturingvaccine platformRSV vaccineshingles vaccinebiotech startupvaccine techtechnology transferimmunogenicity

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Chengdu Maxvax Biotechnology Comps

Public and private peers based on sector, stage, and business model.

Chengdu Maxvax Biotechnology comps — public and private peers by sector, stage, and business model
CompanyStatusEst. ValuationRev Multiple
OpenAIPrivate$86.0B~40x
CoherePrivate$5.0B--
Competitor 1Public$XX.XBXXx
Competitor 2Public$XX.XBXXx

View Full Comps Set

Access detailed peer comparisons, multiples, and valuation benchmarks.

Chengdu Maxvax Biotechnology Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series D ExtensionDec 25, 2025
Series DOct 31, 2025
Series C ExtensionJun 11, 2024
Series CFeb 6, 2024
Series B ExtensionDec 7, 2022
Series B
Jul 20, 2022

Chengdu Maxvax Biotechnology Investors

Notable investors and investment history

Chengdu Maxvax Biotechnology investors
InvestorRounds
GF Qianhe InvestmentSeries B Extension
IDG CapitalSeries D, Series C Extension
Korea Investment PartnersPre Seed
Hillhouse InvestmentSeries B, Series A
Gortune InvestmentSeries B Extension
Korea Investment PartnersSeries A
Guohai Innovation Capital Investment ManagementSeries B Extension

Market signals

Structured signals derived from secondary market and firmographic data.

  • Dec 7, 2022

    $43M round led by GF Qianhe Investment.

Chengdu Maxvax Biotechnology Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Chengdu Maxvax Biotechnology Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Chengdu Maxvax Biotechnology's valuation, stock price, and market status.

Firmographic Details

HeadquartersChengdu
Year Founded2016
Last FundingDec 25, 2025

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.